Straumann combines premium implant leadership, recurring digital consumables and a CHF 177.03 probability-weighted five-year target, despite transition, FX and China pricing risks.
Overview
Straumann is the global premium dental-implant leader, with more than one-third of the premium segment and a portfolio spanning implantology, digital systems and ClearCorrect orthodontics. Its dual-brand strategy pairs high-margin premium products with Neodent and other challenger brands, while SIRIOS X3 scanners and the Straumann AXS cloud ecosystem are designed to secure recurring downstream consumables. **The financial trajectory remains strong:** H1 2026 sales reached CHF 1,379.5 million, up 7.8% organically, with Q2 organic growth accelerating to 8.5%. Core EBIT was CHF 354.8 million, the constant-currency core EBIT margin rose 120 basis points to 26.9%, core net profit increased 15.7% to CHF 262.0 million and FCF grew 49% to CHF 168.6 million. Management reaffirmed upgraded FY2026 guidance for high-single-digit organic growth and 140–170 basis points of core EBIT-margin expansion at constant 2025 exchange rates. At CHF 94.10, the stock trades at 31.5x core FY2025 earnings, but its premium to European Healthcare has compressed to 10% versus a 40% ten-year average. **The valuation case depends on sustained 8.5% normalized organic growth, margin expansion and a smooth CEO transition.** Near-term catalysts include easing China VBP concerns, AXS adoption and institutional target revisions toward CHF 111–130.